XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Previously reported
Retroactive application of recapitalization
Preferred Stock
Preferred Stock
Previously reported
Preferred Stock
Retroactive application of recapitalization
Common Stock
Common Stock
Previously reported
Common Stock
Retroactive application of recapitalization
Additional Paid-in Capital
Additional Paid-in Capital
Previously reported
Additional Paid-in Capital
Retroactive application of recapitalization
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Loss
Previously reported
Accumulated Other Comprehensive Loss
Retroactive application of recapitalization
Accumulated Deficit
Accumulated Deficit
Previously reported
Accumulated Deficit
Retroactive application of recapitalization
Beginning balance (in shares) at Dec. 31, 2020       0 16,383,725 (16,383,725)                        
Beginning balance (in shares) at Dec. 31, 2020             101,286,645 10,838,010 90,448,635                  
Beginning balance at Dec. 31, 2020 $ (18,225) $ (18,225) $ 0 $ 0 $ 62,639 $ (62,639) $ 10 $ 0 $ 10 $ 68,549 $ 5,920 $ 62,629 $ 0 $ 0 $ 0 $ (86,784) $ (86,784) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Issuance of common stock upon exercise of stock options (in shares)             204,119                      
Net settlement of common stock and Series A preferred stock warrants (in shares)             240,806                      
Conversions of convertible note into common stock (in shares)             20,778,097                      
Ending balance (in shares) at Aug. 15, 2021 16,383,725                                  
Beginning balance (in shares) at Dec. 31, 2020       0 16,383,725 (16,383,725)                        
Beginning balance (in shares) at Dec. 31, 2020             101,286,645 10,838,010 90,448,635                  
Beginning balance at Dec. 31, 2020 $ (18,225) $ (18,225) $ 0 $ 0 $ 62,639 $ (62,639) $ 10 $ 0 $ 10 68,549 $ 5,920 $ 62,629 0 $ 0 $ 0 (86,784) $ (86,784) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Stock-based compensation 10,018                 10,018                
Issuance of common stock upon exercise of stock options (in shares)             312,037                      
Issuance of common stock upon exercise of stock options 150                 150                
Business combination and PIPE financing (in shares)             31,894,635                      
Business combination and PIPE financing 256,811           $ 3     256,808                
Transaction costs related to Business Combination and PIPE financing (52,661)                 (52,661)                
Net settlement of common stock and Series A preferred stock warrants (in shares)             240,806                      
Assumption of the private placement warrant liability in connection with Business Combination (268)                 (268)                
Commitment shares for Common Stock Purchase Agreement (in shares)             302,634                      
Issuance of common stock under the Common Stock Purchase Agreement 1,583                 1,583                
Repurchase of stock options (1,500)                 (1,500)                
Issuance of common stock upon vesting of restricted stock units (in shares)             448,604                      
Issuance of common stock upon vesting of restricted stock units 1           $ 1                      
Taxes related to net share settlement of equity awards (in shares)             (126,221)                      
Taxes related to net share settlement of equity awards (835)                 (835)                
Conversions of convertible note into common stock (in shares)             20,778,097                      
Conversions of convertible note into common stock 39,095           $ 2     39,093                
Other comprehensive loss, net of tax (391)                                  
Unrealized loss on available-for-sale debt securities (391)                       (391)          
Net loss $ (65,011)                             (65,011)    
Ending balance (in shares) at Dec. 31, 2021 0     0                            
Ending balance (in shares) at Dec. 31, 2021 155,137,237           155,137,237                      
Ending balance at Dec. 31, 2021 $ 168,767     $ 0     $ 16     320,937     (391)     (151,795)    
Beginning balance (in shares) at Aug. 15, 2021 16,383,725                                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Conversions of convertible note into common stock (in shares)             20,778,097                      
Ending balance (in shares) at Aug. 16, 2021 154,404,302                                  
Beginning balance (in shares) at Dec. 31, 2021 0     0                            
Beginning balance (in shares) at Dec. 31, 2021 155,137,237           155,137,237                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Stock-based compensation $ 23,959                 23,959                
Issuance of common stock upon exercise of stock options (in shares) 3,219,957           3,219,957                      
Issuance of common stock upon exercise of stock options $ 1,174                 1,174                
Commitment shares for Common Stock Purchase Agreement (in shares)             1,145,000                      
Issuance of common stock under the Common Stock Purchase Agreement 2,891                 2,891                
Issuance of common stock upon vesting of restricted stock units (in shares)             3,908,031                      
Taxes related to net share settlement of equity awards (in shares)             (1,340,810)                      
Taxes related to net share settlement of equity awards (3,790)                 (3,790)                
Transaction costs related to the Common Stock Purchase Agreement $ (29)                 (29)                
Issuance of common stock upon exercise of public warrants (in shares)             10                      
Conversions of convertible note into common stock (in shares) 1,029,699                                  
Conversions of convertible note into common stock $ 600                                  
Other comprehensive loss, net of tax (888)                       (888)          
Unrealized loss on available-for-sale debt securities (940)                                  
Net loss $ (98,714)                             (98,714)    
Ending balance (in shares) at Dec. 31, 2022 0     0                            
Ending balance (in shares) at Dec. 31, 2022 163,099,124           163,099,124                      
Ending balance at Dec. 31, 2022 $ 93,970     $ 0     $ 16     $ 345,742     $ (1,279)     $ (250,509)